UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 18 von 152
Datensatz exportieren als...
BibTeX
Salvage chemotherapy with cyclophosphamide for recurrent temozolomide‐refractory anaplastic astrocytoma
Cancer, 2006-01, Vol.106 (1), p.172-179
Chamberlain, Marc C.
Tsao‐Wei, Denice D.
Groshen, Susan
2006
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Chamberlain, Marc C.
Tsao‐Wei, Denice D.
Groshen, Susan
Titel
Salvage chemotherapy with cyclophosphamide for recurrent temozolomide‐refractory anaplastic astrocytoma
Ist Teil von
Cancer, 2006-01, Vol.106 (1), p.172-179
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2006
Quelle
Wiley Online Library Journals Frontfile Complete
Beschreibungen/Notizen
BACKGROUND A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide‐refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6‐month progression‐free survival (PFS). METHODS Forty patients (28 men, 12 women) ages 26–57 years (median, 43 yrs) with neuroradiographically recurrent AA were treated. All patients had previously been treated with surgery and involved‐field radiotherapy. Additionally, all patients were treated with temozolomide (TMZ) chemotherapy after radiotherapy. All patients were treated at recurrence with CYC administered intravenously on 2 consecutive days (750 mg/m2/day) every 4 weeks (operationally defined as a single cycle). Neurologic and neuroradiographic evaluation were performed every 8 weeks. RESULTS All patients were evaluable. A total of 215 cycles of CYC (median, 4 cycles; range 2–12 cycles) was administered. CYC‐related toxicity included alopecia (all patients, 100%), anemia (5, 12.5%), thrombocytopenia (6, 15%), and neutropenia (8, 20%). Four (10%) patients required transfusion. Nine patients (22.5%) (95% confidence interval [95% CI], 11%–39%) demonstrated a neuroradiographic partial response, 16 patients (40.0%) (95% CI, 25%–57%) demonstrated stable disease, and 15 patients (37.5%) (95% CI, 23%–54%) had progressive disease after 2 cycles of CYC. Time to tumor progression ranged from 2–19 months (median, 4 mos; 95% CI, 2–6 mos). Survival ranged from 2–26 months (median, 8 mos; 95% CI, 6–10 mos). The 6‐month and 12‐month PFS was 30% and 8%, respectively. CONCLUSIONS CYC demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent anaplastic astrocytoma, all of whom had failed prior TMZ chemotherapy. Cancer 2006. © 2005 American Cancer Society. A prospective Phase II study of cyclophosphamide was conducted in adult patients with recurrent temozolomide‐refractory anaplastic astrocytoma with a primary objective of evaluating 6‐month progression‐free survival.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.21582
Titel-ID: cdi_crossref_primary_10_1002_cncr_21582
Format
–
Schlagworte
Adult
,
Anaplasia
,
Antineoplastic Agents, Alkylating - administration & dosage
,
Antineoplastic Agents, Alkylating - adverse effects
,
Antineoplastic Agents, Alkylating - therapeutic use
,
Astrocytoma - drug therapy
,
Astrocytoma - pathology
,
Biological and medical sciences
,
Brain Neoplasms - drug therapy
,
Brain Neoplasms - pathology
,
cyclophosphamide
,
Cyclophosphamide - administration & dosage
,
Cyclophosphamide - adverse effects
,
Cyclophosphamide - therapeutic use
,
Dacarbazine - analogs & derivatives
,
Dacarbazine - therapeutic use
,
Drug Administration Schedule
,
Drug Resistance, Neoplasm
,
efficacy
,
Female
,
Humans
,
Male
,
Medical sciences
,
Middle Aged
,
Neoplasm Recurrence, Local - drug therapy
,
Neurology
,
Prospective Studies
,
recurrent anaplastic astrocytoma
,
Salvage Therapy
,
temozolomide
,
toxicity
,
Tumors
,
Tumors of the nervous system. Phacomatoses
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX